ARCHIVES

Texas Oncology Designated Aranesp As Preferred Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 46 | December 13, 2002

Download PDF Visit The Full Archive

Related Articles

Trial Data: No Benefit In Adding Perifosine to Capecitabine

June 29, 2012

Duke Insiders Allege Intimidation By Administration

July 23, 2010

NCI Diet Guideline Outlined At Senate Hearing

November 22, 1985

New RFAs on Retinoids & Carotenoids, Tobacco, NMR Research Resistance

July 27, 1984

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

April 6, 2012

In Brief: Cancer Program Bill Renews Congressional Commitment To Principles, Rep. Carter Says

May 5, 1978